Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 51, Issue 9


Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay

Jin Kyung Rho
  • Asan Institute for Life Sciences, Department of Pulmonary and Critical Care Medicine, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hyangsin Lee / Chan-Sik Park / Chang-Min Choi
  • Asan Institute for Life Sciences, Department of Pulmonary and Critical Care Medicine, Seoul, Korea
  • Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jae Cheol Lee
Published Online: 2013-04-09 | DOI: https://doi.org/10.1515/cclm-2013-0044


Background: EML4-ALK fusion oncogene has emerged as a novel molecular target in non-small cell lung cancer (NSCLC). Although break-apart fluorescent in situ hybridization (FISH) is the standard method for diagnosis, it is expensive, not readily available and sometimes difficult to interpret. In addition, ALK immunohistochemistry (IHC) may miss the diagnosis because of relatively low level of ALK transcription.

Methods: In situ proximity ligation assay (PLA) originally developed for precise detection and quantification of proteins by dual recognition and amplification process was used for sensitive detection of EML4-ALK fusion oncoprotein in NSCLC cell lines (ALK negative cell: PC-9 and H460, ALK positive cell: H3122 and H2228). EML4-ALK oncogene and protein in lung cancer cells were confirmed by multiplex RT-PCR and Western blots.

Results: We detected 117 kDa variant 1 of EML4-ALK in H3122 and 90 kDa variant 3 of EML4-ALK in H2228. These cells were more sensitive to crizotinib, an ALK inhibitor compared with PC-9 and H460 cells without EML4-ALK rearrangement. After fixing on glass slides by cytospin centrifuge, in situ PLA test was performed. Among four cell lines, distinct, tiny spots were visible only in H3122 and H2228 cell lines with ALK rearrangement. The same results were also obtained when paraffin-embedded cell blocks were used.

Conclusions: Highly specific and sensitive detection of EML4-ALK fusion oncoprotein is possible by in situ PLA method suggesting its clinical application.

Keywords: diagnosis; EML4-ALK; lung cancer


  • 1.

    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.Web of ScienceGoogle Scholar

  • 2.

    Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893–7.Google Scholar

  • 3.

    Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143–9.Web of SciencePubMedCrossrefGoogle Scholar

  • 4.

    Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190–203.Google Scholar

  • 5.

    Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–703.Web of ScienceGoogle Scholar

  • 6.

    Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216–23.CrossrefWeb of SciencePubMedGoogle Scholar

  • 7.

    Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408–17.Web of ScienceGoogle Scholar

  • 8.

    Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17:1351–75.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 9.

    McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348–54.Web of ScienceCrossrefGoogle Scholar

  • 10.

    Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of ALK rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011;6:466–72.CrossrefWeb of SciencePubMedGoogle Scholar

  • 11.

    Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661–70.Google Scholar

  • 12.

    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936–42.PubMedGoogle Scholar

  • 13.

    Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of fas in non-small cell lung cancer. Cancer Res 2007;67:1163–9.Google Scholar

  • 14.

    Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618–24.Web of ScienceCrossrefGoogle Scholar

  • 15.

    Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723–33.Web of ScienceGoogle Scholar

  • 16.

    Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2012;119. Epub ahead of print 20 Dec 2012. DOI: 10.1002/CNCR.27913.CrossrefGoogle Scholar

  • 17.

    Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013;8:45–51.CrossrefWeb of SciencePubMedGoogle Scholar

  • 18.

    Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288–92.Web of ScienceGoogle Scholar

  • 19.

    Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995–1000.CrossrefGoogle Scholar

  • 20.

    Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863–70.CrossrefWeb of ScienceGoogle Scholar

  • 21.

    Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET Fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 22.

    Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378–81.PubMedGoogle Scholar

About the article

Corresponding author: Jae Cheol Lee, MD, PhD, Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, 388–1 Pungnap-2 Dong, Songpa-Gu, Seoul 138–736, Korea, Phone: +82 2 30103208, Fax: +82 2 30106961

Received: 2013-01-17

Accepted: 2013-03-18

Published Online: 2013-04-09

Published in Print: 2013-09-01

Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 51, Issue 9, Pages 1843–1848, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0044.

Export Citation

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in